SCHEMBL3012932

SCHEMBL3012932

CCCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(OC)cc4)CC3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.56
RAB9A P51151 5/20 0.56
KCNQ1 P51787 1/20 0.55
MAPT P10636 7/20 0.54
NPC1 O15118 3/20 0.53
ALDH1A1 P00352 6/20 0.50
LMNA P02545 6/20 0.49
MAPK1 P28482 5/20 0.49
POLB P06746 2/20 0.47
USP2 O75604 3/20 0.47
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47
HTT P42858 1/20 0.47
MMP1 P03956 1/20 0.45
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45
MMP9 P14780 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006770 0.93 SMN1; SMN2 (0.57) SMN1; SMN2RAB9AKCNQ1MAPTNPC1
SCHEMBL2998857 0.91 SMN1; SMN2 (0.65) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3004456 0.90 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AKCNQ1MAPTNPC1
SCHEMBL3015007 0.90 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AKCNQ1MAPTNPC1
SCHEMBL3014489 0.89 KCNQ1 (0.45) SMN1; SMN2RAB9AKCNQ1MAPTNPC1
SCHEMBL3013304 0.89 SMN1; SMN2 (0.57) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3017814 0.89 MAPT (0.52) SMN1; SMN2RAB9AKCNQ1MAPTNPC1
SCHEMBL3010392 0.89 KMT2A (0.46) SMN1; SMN2RAB9AKCNQ1MAPTNPC1
SCHEMBL3009746 0.89 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AKCNQ1MAPTNPC1
SCHEMBL3006360 0.89 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AKCNQ1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885KCNQ1 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.